GSK’s Patrick Vallance on a new generation antibiotics
- Related tags:
GSK’s President of Pharmaceutical R&D explains why GSK is involved in challenging antibiotics resistance.
Explore more features
How we do business
Andrew Witty, Chief Executive Officer, GSK, discusses antibiotic effectiveness, the issues surrounding drug pricing and corporate inversions. He speaks to Bloomberg's Jonathan Ferro and Hans Nichols on "Countdown" from the World Economic Forum in Davos, Switzerland, January 2016.